DNLI: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-383,991	-257,089
Depreciation and amortization	8,317	5,370
Stockbased compensation expense	75,682	50,547
Net accretion of discounts on marketable securities	8,611	6,585
Non-cash adjustment to operating lease expense	3,305	2,161
Right-of-use asset amortization for finance lease	2,713	1,798
Non-cash gain from divestiture of small molecule programs	0	0
Prepaid expenses and other current assets	2,287	3,650
Other non-current assets	-1,305	-3,022
Accounts payable	-4,112	-43
Accruals and other current liabilities	-12,262	-14,151
Deferred research and development funding liability	12,489	16,176
Net cash used in operating activities	-314,062	-206,766
Purchases of marketable securities	188,555	137,926
Maturities and sales of marketable securities	431,046	323,965
Purchases of property and equipment	7,978	9,356
Net cash provided by (used in) investing activities	234,513	176,683
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480	0	0
Proceeds from exercise of awards under equity incentive plans	5,235	4,652
Payments for finance lease right-of-use asset	8,152	6,791
Net cash (used in) provided by financing activities	-2,917	-2,139
Net decrease in cash, cash equivalents and restricted cash	-82,466	-32,222
Cash and cash equivalents at beginning of period	176,535	-
Cash and cash equivalents at end of period	94,069	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

DNLI: the cashflow